Citizens Financial Group Inc. RI Has $1.59 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Citizens Financial Group Inc. RI increased its holdings in Gilead Sciences by 41.3% during the 1st quarter, bringing its total shares to 14,172 and valued at approximately $1.59 million.
• Insider transactions revealed that CFO Andrew D. Dickinson and Director Jeffrey Bluestone sold shares, with Dickinson selling 2,500 shares and Bluestone selling 5,000 shares.
• Gilead Sciences reported an EPS of $2.01 for the last quarter, exceeding analysts' expectations and showing 1.4% year-over-year revenue growth with total revenue of $7.08 billion.

Citizens Financial Group Inc. RI boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 41.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,172 shares of the biopharmaceutical company's stock after purchasing an additional 4,145 shares during the period. Citizens Financial Group Inc. RI's holdings in Gilead Sciences were worth $1,588,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of GILD. Bridgewater Associates LP lifted its holdings in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after purchasing an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its holdings in Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 109 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its holdings in Gilead Sciences by 54.6% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock worth $3,422,000 after purchasing an additional 13,086 shares during the last quarter. Finally, Mufg Securities Americas Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $1,699,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares of the company's stock, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $8,984,175 over the last 90 days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Trading Down 0.2%

NASDAQ GILD traded down $0.25 on Tuesday, hitting $120.22. The company's stock had a trading volume of 1,897,911 shares, compared to its average volume of 8,377,158. The company's 50-day moving average is $111.16 and its 200 day moving average is $107.83. Gilead Sciences, Inc. has a 1-year low of $72.67 and a 1-year high of $121.83. The firm has a market cap of $149.17 billion, a PE ratio of 23.96, a PEG ratio of 0.75 and a beta of 0.33. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the company posted $2.01 EPS. The business's revenue was up 1.4% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

Analyst Ratings Changes

Several analysts recently weighed in on GILD shares. Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $108.00 to $127.00 in a research report on Friday. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a research report on Friday, July 25th. Finally, UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $114.82.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.